1 / 64

B B

P P. B B. Dornhorst: Lancet 1955. Hogg J et al. NEJM 2004. Hogg J et al. NEJM 2004. Flow-Volume Curve. Normal. Severe-obstruction. From Pride N. in Calverley PMA: COPD, 1995. ROCA J. 2002. Emphysema by CT scan.

thisbe
Download Presentation

B B

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. P P B B Dornhorst: Lancet 1955

  2. Hogg J et al. NEJM 2004

  3. Hogg J et al. NEJM 2004

  4. Flow-Volume Curve Normal Severe-obstruction From Pride N. in Calverley PMA: COPD, 1995

  5. ROCA J. 2002

  6. Emphysema by CT scan Poor correlation with mild anatomical emphysema. Moderate correlation with function Does not detect PLE of degrees as high as 30/100. Emphysema can be present with normal function.

  7. West J. Respiratory Physiology: the essentials. 1985

  8. FEV1/FVC = ridotto FVC = ridotto L’IMPORTANZA DI MISURARE TLC Ostruzione oppure Ostruzione e restrizione?

  9. OBSTRUCTION (PSEUDORESTRICTION) RESTRICTION FEV1/FVC = normale FVC = ridotto L’IMPORTANZA DI MISURARE TLC Ostruzione o Restrizione ?

  10. ALTRI ACCERTAMENTI (4) a cura dello pneumologo ANOMALIA OSTRUTTIVA? ANOMALIA OSTRUTTIVA? PERSONA A RISCHIO (2) STOP SINTOMI RESPIRATORI? (1) SI’ NO NO SPIROMETRIA GLOBALE + TEST DI BRONCODILATAZIONE + EVENTUALE VISITA PNEUMOLOGICA (3) NO SI’ SI’ SI’ DIAGNOSI DI BPCO SPIROMETRIA SEMPLICE + TEST DI BRONCODILATAZIONE + EVENTUALE VISITA PNEUMOLOGICA (3) NO FOLLOW UP STADIAZIONE E TRATTAMENTO a cura dello pneumologo • Ricerca attiva dei sintomi, anche con questionari ad hoc, ogni 1-2 anni, se presente rischio • Utilizzo carte del rischio CNR-ISS • Spirometria semplice • Per altre malattie respiratorie o di altri apparati. MMG PERCORSO DIAGNOSTICO DELLA BPCO

  11. “IF PULMONARY FELLOWS BEGINNING THEI TRAINING FULLY UNDERSTOOD ALL THE MATERIAL ON GAS EXCHANGE AND MECHANICS, THE WORLD WOULD BE A BETTER PLACE”. • John West. Respiratory Physiology. The Essential. 2005

  12. 25

  13. Lung volumes during exercise: dynamic hyperinflation in COPD IRV = inspiratory reserve volume

  14. 28

  15. 29

  16. 37

  17. 38

  18. International Jourmal COPD 2011

  19. FVC FEV1<65%pr Testo

  20. 300 + 300 pts six weeks

  21. 46

  22. Rate of moderate and severe exacerbations over three years Mean number of exacerbations/year 25% reduction 1.2 1.13 0.97* 0.93* 1 0.85*†‡ 0.8 0.6 0.4 0.2 0 Placebo SALM FP SALM/FP Treatment *p < 0.001 vs placebo; †p = 0.002 vs SALM; ‡p = 0.024 vs FP

  23. NOTA EMA-AIFA • Per salmeterolo50/Fluticasone500 mcg bid “trattamento sintomatico di pazienti con BPCO, con FEV1<60% del predetto pre-broncodilatatore ed una storia di riacutizzazioni ripetute, che abbiano sintomi significativi nonostante la terapia regolare con broncodilatatori”. 50

More Related